How to eliminate solid tumors by CAR T-cell therapy

Abstract

T cells expressing chimeric antigen receptors (CART) have shown significant promise in clinical trials to treat hematologic malignancies, but their efficacy in solid tumors has been limited ,It's because solid tumors don't seem to be the identical . Oncolytic viruses have the potential to act in synergy with immunotherapies because of their immunogenic oncolytic properties and also the opportunity of incorporating therapeutic transgenes in their genomes. hypothesized that an oncolytic adenovirus armed with an EGFR-targeting, bispecific T-cell engager (OAd-BiTE) would improve the end result of CART-cell therapy in solid tumors. demonstrated that OAd-BiTE– mediated oncolysis significantly improved CART-cell activation and proliferation, while increasing cytokine production and cytotoxicity, and showed an in vitro favorable safety profile. BiTEs secreted from infected cells redirected CART cells toward EGFR within the absence of FR-a, thereby addressing tumor heterogeneity. BiTE secretion also redirected CAR-negative, nonspecific T cells found in CART-cell preparations toward tumor cells.